1. Home
  2. TXG vs MLYS Comparison

TXG vs MLYS Comparison

Compare TXG & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 10x Genomics Inc.

TXG

10x Genomics Inc.

HOLD

Current Price

$24.95

Market Cap

2.3B

Sector

Industrials

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$27.18

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TXG
MLYS
Founded
2012
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.2B
IPO Year
2019
2023

Fundamental Metrics

Financial Performance
Metric
TXG
MLYS
Price
$24.95
$27.18
Analyst Decision
Hold
Strong Buy
Analyst Count
15
6
Target Price
$17.61
$48.67
AVG Volume (30 Days)
2.2M
1.2M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
76.97
37.43
EPS
N/A
N/A
Revenue
$245,893,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
68.06
N/A
52 Week Low
$7.26
$12.59
52 Week High
$24.30
$47.65

Technical Indicators

Market Signals
Indicator
TXG
MLYS
Relative Strength Index (RSI) 70.86 53.22
Support Level $11.62 $26.85
Resistance Level N/A $31.09
Average True Range (ATR) 1.14 1.65
MACD 0.41 0.38
Stochastic Oscillator 93.57 62.11

Price Performance

Historical Comparison
TXG
MLYS

About TXG 10x Genomics Inc.

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: